What are the two pillars of treatment for a patent with AVWS?Click for Answer
AVWS, acquired von Willebrand syndrome
For management of bleeding in a patient with acquired von Willebrand syndrome (AVWS), what are reasonable options?
Other management options for active bleeding include:
- Intravenous immunoglobulin (IVIG)
- Recombinant activated factor VII (FVIIa)
Why is the response to DDAVP and VWF concentrates often short lasting?Click for Answer
In this case, the patient’s postoperative bleeding had resolved and he did not require vWF/FVIII concentrates or DDAVP. He was treated for his Waldenstrom’s macroglobulinemia (WM) with the hope that this would improve the acquired von Willebrand syndrome (AVWS). The patient did not have any symptoms of hyperviscosity from his WM and he was not actively bleeding, so he did not require plasmapheresis. Instead, he received combination therapy with dexamethasone, rituximab and cyclophosphamide. Over the next 6 months, his IgM levels decreased and his vWF antigen and activity levels increased. He did not have recurrence of iron deficiency anemia.
Consider a different patient with acquired von Willebrand syndrome (AVWS) resulting from essential thrombocythemia. His platelet count is 1,600 x 109/L. He is being treated for this essential thrombocythemia with hydroxyurea and low dose aspirin per clinical practice guideline recommendations.